FAKTOR-OPTIONSSCHEIN - MODERNA | Delayed Deutsche Boerse AG 15:36:45 2024-05-30 EDT | ||
| 0.29 EUR | -9.38% |
|
| Current month | -75.00% | ||
| 1 month | -75.00% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
Latest news about MODERNA, INC.
| Date | Price | Change |
|---|---|---|
| 24-05-30 | 0.29 | -9.38% |
| 24-05-29 | 0.32 | +10.34% |
| 24-05-28 | 0.29 | +26.09% |
| 24-05-27 | 0.23 | 0.00% |
| 24-05-24 | 0.23 | -4.17% |
Delayed Quote Deutsche Boerse AG
Last update May 30, 2024 at 03:36 pm
More quotesStatic data
| Product type | Produits Exotiques |
|---|---|
| Buy / Sell | CALL |
| Underlying | MODERNA, INC. |
| Issuer | 
Société Générale
|
| WKN | SF4DZ9 |
| ISIN | DE000SF4DZ99 |
| Date issued | 2021-09-10 |
| Strike | 422.8 $ |
| Maturity | Unlimited |
| Parity | 1 : 1 |
| Emission price | 25.12 € |
| Emission volume | N/A |
| Settlement | règlement en espèces |
| Currency | EUR |
Technical Indicators
| Highest since issue | 102.1 € |
|---|---|
| Lowest since issue | 0.22 € |
| Spread | 0.01 € |
| Spread % | 3.23% |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
151.5
USD
Average target price
138.8
USD
Spread / Average Target
-8.39%
- Stock Market
- Certificates
- Certificat
